Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), has named Juan Carlos Lopez-Talavera as senior vice president of medical affairs.

“Juan Carlos brings more than 20 years of industry and academic experience to Intercept and is a globally recognized hepatologist,” said David Shapiro, chief medical officer. “We will benefit greatly from Juan Carlos’s considerable expertise in working with the medical community to enhance understanding of underserved liver diseases and strategies for improving patient care.”

Dr. Lopez-Talavera most recently served as head of hepatology R&D and vice president of medical affairs at Abbvie, where he was responsible for all medical affairs activities supporting the global launch of Abbvie’s regimen for the treatment of Hepatitis C.